News + Resources
ABA Antitrust Podcast: Balanced Approach is Critical to Assessing the Impact of Life Sciences M&A on Innovation
On a recent episode of the ABA Antitrust Podcast Our Curious Amalgam, Dr. Penka Kovacheva, Cornerstone Research Vice President and lead author of a paper recently published in Concurrences, “The Impact of Pharmaceutical M&A on Innovation,” discusses many ways in...
ICYMI – BioPharma Dive: Increased Biopharmaceutical M&A Critical to Supporting Early-Stage Breakthroughs
A recent article from BioPharma Dive highlights the challenging landscape for biopharmaceutical initial public offerings (IPOs), and the critical role that mergers & acquisitions play in connecting promising innovations with the resources and investment needed to...
Concurrences Law & Economics: M&A Unlocks Economies of Scale and Scope Across the Life Sciences Ecosystem
In a recent article published in Concurrences Law & Economics, Cornerstone Research experts Lorenzo Cattivelli, Anca Cojoc, Penka Kovacheva and Maria Salgado highlight ways that mergers and acquisitions (M&A) can contribute to innovation in the...
ICYMI: Ways and Means Field Hearing – Policymakers Must Take a Balanced, Bipartisan Approach to Life Sciences M&A
The U.S. House Committee on Ways and Means recently held a field hearing in Salt Lake City, UT: “Access to Health Care in America: Unleashing Medical Innovation and Economic Prosperity.” While discussing the many challenges and unique market dynamics that shape life...
Innovations Advanced by M&A: Breakthrough Treatments for Rare, Aggressive Cancers
By combining complementary resources and expertise among companies of all sizes – while driving investment across the ecosystem – M&A helps advance innovative new treatments and cures to patients. This was precisely the case for Retevmo and Jaypirica, two first-of-their-kind oncology treatments brought to market through the acquisition of Loxo Oncology by Eli Lilly & Co.